Cantor Fitzgerald Issues Negative Forecast for HRMY Earnings

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY - Free Report) - Investment analysts at Cantor Fitzgerald decreased their FY2025 earnings per share estimates for shares of Harmony Biosciences in a research report issued on Wednesday, February 26th. Cantor Fitzgerald analyst C. Duncan now forecasts that the company will post earnings of $2.43 per share for the year, down from their prior estimate of $3.27. The consensus estimate for Harmony Biosciences' current full-year earnings is $2.43 per share.

A number of other equities research analysts also recently commented on HRMY. HC Wainwright decreased their target price on Harmony Biosciences from $75.00 to $70.00 and set a "buy" rating on the stock in a research report on Thursday. Deutsche Bank Aktiengesellschaft assumed coverage on Harmony Biosciences in a report on Tuesday, February 11th. They set a "buy" rating and a $55.00 price objective on the stock. Needham & Company LLC reissued a "buy" rating and issued a $50.00 target price on shares of Harmony Biosciences in a report on Tuesday, February 25th. Finally, Mizuho decreased their price target on shares of Harmony Biosciences from $52.00 to $42.00 and set an "outperform" rating on the stock in a research note on Thursday, February 20th. Nine analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has an average rating of "Buy" and an average price target of $53.11.

Harmony Biosciences Price Performance

HRMY stock traded down $1.67 during mid-day trading on Friday, hitting $32.18. The company had a trading volume of 747,426 shares, compared to its average volume of 644,598. The company has a market capitalization of $1.85 billion, a price-to-earnings ratio of 15.25, a P/E/G ratio of 0.47 and a beta of 0.80. The company has a 50-day moving average price of $36.63 and a 200 day moving average price of $35.81. The company has a quick ratio of 3.20, a current ratio of 3.24 and a debt-to-equity ratio of 0.28. Harmony Biosciences has a 12-month low of $28.14 and a 12-month high of $41.61.

Harmony Biosciences (NASDAQ:HRMY - Get Free Report) last released its earnings results on Tuesday, February 25th. The company reported $0.85 EPS for the quarter, topping the consensus estimate of $0.74 by $0.11. The firm had revenue of $201.30 million for the quarter, compared to the consensus estimate of $201.25 million. Harmony Biosciences had a net margin of 17.98% and a return on equity of 23.16%. The company's quarterly revenue was up 19.5% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.45 earnings per share.

Institutional Trading of Harmony Biosciences

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Hillsdale Investment Management Inc. grew its holdings in shares of Harmony Biosciences by 0.4% in the fourth quarter. Hillsdale Investment Management Inc. now owns 68,000 shares of the company's stock worth $2,340,000 after purchasing an additional 300 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its position in Harmony Biosciences by 21.2% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,056 shares of the company's stock valued at $80,000 after buying an additional 360 shares during the period. O Shaughnessy Asset Management LLC grew its stake in Harmony Biosciences by 2.1% in the 4th quarter. O Shaughnessy Asset Management LLC now owns 20,450 shares of the company's stock worth $704,000 after acquiring an additional 420 shares in the last quarter. GAMMA Investing LLC grew its stake in Harmony Biosciences by 92.6% in the 4th quarter. GAMMA Investing LLC now owns 907 shares of the company's stock worth $31,000 after acquiring an additional 436 shares in the last quarter. Finally, PNC Financial Services Group Inc. increased its position in shares of Harmony Biosciences by 28.7% during the fourth quarter. PNC Financial Services Group Inc. now owns 2,328 shares of the company's stock worth $80,000 after acquiring an additional 519 shares during the period. Hedge funds and other institutional investors own 86.23% of the company's stock.

Insider Buying and Selling

In other news, CFO Sandip Kapadia sold 1,775 shares of the stock in a transaction that occurred on Monday, January 27th. The stock was sold at an average price of $38.05, for a total value of $67,538.75. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, insider Jeffrey Dierks sold 1,123 shares of the business's stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $40.00, for a total value of $44,920.00. The disclosure for this sale can be found here. Insiders sold a total of 72,452 shares of company stock worth $2,831,679 over the last three months. 30.80% of the stock is owned by insiders.

Harmony Biosciences Company Profile

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.